去势抵抗性前列腺癌患者使用醋酸阿比特龙治疗后发生前列腺特异性抗原闪烁现象的相关因素
| 作者: |
1李俊,
1杜鸿,
1熊国兵,
1廖勇,
1黄翔,
1邱明星
1 四川省医学科学院·四川省人民医院泌尿外科，成都 610072 |
| 通讯: |
李俊
Email: april0429@qq.com |
| DOI: | 10.3978/j.issn.2095-6959.2018.06.015 |
摘要
目的：分析去势抵抗性前列腺癌(castration-resistant prostate cancer，CRPC)患者应用醋酸阿比特龙联合泼尼松治疗早期出现前列腺特异性抗原闪烁(prostate specific antigen flare，PSA Flare)现象后对患者特异性前列腺抗原(prostate specific antigen，PSA)下降水平和无进展生存时间(progress free sur vival，PFS)的影响。方法：共纳入2015年10月至2017年10月接受醋酸阿比特龙联合泼尼松治疗的55例CRPC患者，长期随访并记录治疗期间血清PSA等检查资料，动态观察患者疾病变化情况。结果：患者持续有效ADT内分泌治疗时间的不同对PSA Flare的出现有一定的影响。PSA Flare的出现不会影响PSA下降水平，但会在一定程度上积极影响患者达到PSA缓解水平的疗效。PSA Flare的出现对患者的PFS无明显影响。结论：使用醋酸阿比特龙联合泼尼松治疗CRPC患者中，PSA Flare的出现对患者达到PSA缓解具有一定的积极意义。
关键词：
去势抵抗性前列腺癌；醋酸阿比特龙；前列腺特异性抗原闪烁；PSA缓解率；前列腺特异性抗原
Related factors of prostate specific antigen flare phenomenon in patients with Castration-resistant prostate cancer after treatment with abiraterone acetate
CorrespondingAuthor: LI Jun Email: april0429@qq.com
DOI: 10.3978/j.issn.2095-6959.2018.06.015
Abstract
Objective: To analyze the effect of prostate specific antigen flare (PSA flare) on the level of PSA decline and the progression free survival time of patients with castration-resistant prostate cancer (CRPC) with abiraterone acetate and prednisone acetate in the early stage of treatment. Methods: The clinical data of 55 CRPC patients who were treated with prednisone from October 2015 to October 2017 were enrolled in the study. Long-term follow up and record the prostate specific antigen (PSA) and other data during treatment. Results: The duration of continuous effective endocrine therapy had a certain effect on the occurrence of PSA flare. The occurrence of PSA flare affected the level of PSA decline, but it positively affected the curative effect of PSA to a certain extent. The presence of PSA Flare had no significant effect on PFS in patients. Conclusion: In the treatment of CRPC patients, the presence of PSA Flare has a positive effect on PSA relief.
Keywords：
castration-resistant prostate cancer; abiraterone acetate; prostate specific antigen flare; PSA response rate; prostate specific antigen